FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer

Merck’s Keytruda plus Pfizer’s Padcev received FDA approval for expanded use in muscle-invasive bladder cancer, for patients regardless of cisplatin eligibility. The label expansion is a meaningful incremental indication that can broaden addressable demand beyond the cisplatin-eligible population. Overall read-through for both companies is positive on potential uptake and long-term growth prospects.

Analysis

Merck’s Keytruda plus Pfizer’s Padcev received FDA approval for expanded use in muscle-invasive bladder cancer, for patients regardless of cisplatin eligibility. The label expansion is a meaningful incremental indication that can broaden addressable demand beyond the cisplatin-eligible population. Overall read-through for both companies is positive on potential uptake and long-term growth prospects.